Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes (iINHALE 7)
Efficacy and Safety of Inhaled Prandial Insulin Compared to Metformin Plus Glimepiride in Type 2 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, B1636DSU
- Novo Nordisk Investigational Site
-
Buenos Aires, Argentina, C1425AGC
- Novo Nordisk Investigational Site
-
Ciudad de Mendoza, Argentina, 5500
- Novo Nordisk Investigational Site
-
Mar del Plata, Argentina, B7600FZN
- Novo Nordisk Investigational Site
-
-
-
-
-
Ebreichsdorf, Austria, 2483
- Novo Nordisk Investigational Site
-
Kittsee, Austria, A 2421
- Novo Nordisk Investigational Site
-
Salzburg, Austria, 5020
- Novo Nordisk Investigational Site
-
Wien, Austria, 1130
- Novo Nordisk Investigational Site
-
Wien, Austria, A 1160
- Novo Nordisk Investigational Site
-
-
-
-
-
Arlon, Belgium, 6700
- Novo Nordisk Investigational Site
-
Bonheiden, Belgium, 2820
- Novo Nordisk Investigational Site
-
Borsbeek, Belgium, 2150
- Novo Nordisk Investigational Site
-
Gent, Belgium, 9000
- Novo Nordisk Investigational Site
-
Huy, Belgium, 4500
- Novo Nordisk Investigational Site
-
Leuven, Belgium, 3000
- Novo Nordisk Investigational Site
-
-
-
-
-
Sofia, Bulgaria, 1431
- Novo Nordisk Investigational Site
-
Sofia, Bulgaria, 1606
- Novo Nordisk Investigational Site
-
-
-
-
-
Mississauga, Canada, L5M 2V8
- Novo Nordisk Investigational Site
-
Oshawa, Canada, L1J 2K1
- Novo Nordisk Investigational Site
-
Saskatoon, Canada, S7N 0W8
- Novo Nordisk Investigational Site
-
Trois-Rivieres, Canada, G8T 7A1
- Novo Nordisk Investigational Site
-
-
Alberta
-
Edmonton, Alberta, Canada, T5J 3N4
- Novo Nordisk Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 3P4
- Novo Nordisk Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Novo Nordisk Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Novo Nordisk Investigational Site
-
Smiths Falls, Ontario, Canada, K7A 4W8
- Novo Nordisk Investigational Site
-
-
Quebec
-
Laval, Quebec, Canada, H7T 2P5
- Novo Nordisk Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Novo Nordisk Investigational Site
-
-
-
-
-
Corbeil Essonnes, France, 91106
- Novo Nordisk Investigational Site
-
NEVERS cedex, France, 58033
- Novo Nordisk Investigational Site
-
Nantes, France, 44093
- Novo Nordisk Investigational Site
-
Narbonne, France, 11108
- Novo Nordisk Investigational Site
-
Paris, France, 75877
- Novo Nordisk Investigational Site
-
Roubaix, France, 59100
- Novo Nordisk Investigational Site
-
-
-
-
-
Bangalore, India, 560041
- Novo Nordisk Investigational Site
-
Coimbatore, India, 641002
- Novo Nordisk Investigational Site
-
Hyderabad, India, 600034
- Novo Nordisk Investigational Site
-
Thriruvananthapuram, India, 695 032
- Novo Nordisk Investigational Site
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, India, 452010
- Novo Nordisk Investigational Site
-
-
-
-
-
Beer Sheva, Israel, 84101
- Novo Nordisk Investigational Site
-
Holon, Israel, 58100
- Novo Nordisk Investigational Site
-
Jerusalem, Israel, 91120
- Novo Nordisk Investigational Site
-
-
-
-
-
Guadalajara, Mexico, 44600
- Novo Nordisk Investigational Site
-
Mexico city, Mexico, 03100
- Novo Nordisk Investigational Site
-
Mexico city, Mexico, 11650
- Novo Nordisk Investigational Site
-
-
México, D.F.
-
Mexico City, México, D.F., Mexico, 14000
- Novo Nordisk Investigational Site
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64460
- Novo Nordisk Investigational Site
-
-
-
-
-
Gdansk, Poland, 80-858
- Novo Nordisk Investigational Site
-
Lodz, Poland, 90-030
- Novo Nordisk Investigational Site
-
Lublin, Poland, 20-044
- Novo Nordisk Investigational Site
-
Lublin, Poland, 20-538
- Novo Nordisk Investigational Site
-
Mazowieckie, Poland, 09-400
- Novo Nordisk Investigational Site
-
Rawa Mazowiecka, Poland, 96-200
- Novo Nordisk Investigational Site
-
Warszawa, Poland, 02-097
- Novo Nordisk Investigational Site
-
Zabrze, Poland, 41-800
- Novo Nordisk Investigational Site
-
-
-
-
-
Istanbul, Turkey, 34718
- Novo Nordisk Investigational Site
-
Istanbul, Turkey, 34371
- Novo Nordisk Investigational Site
-
Istanbul, Turkey, 34093
- Novo Nordisk Investigational Site
-
Konya, Turkey, 42001
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes
- Treated with OADs for more than or equal to 3 months
- HbA1c greater than or equal to 8.0% and less than or equal to 11.0%
- Body Mass Index (BMI) less than or equal to 40.0 kg/m2
Exclusion Criteria:
- Recurrent major hypoglycaemia
- Current smoking or smoking within the last 6 months
- Impaired hepatic or renal function
- Cardiac problems
- Uncontrolled hypertension
- Proliferative retinopathy or maculopathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: B
|
Treat-to-target dose titration scheme, pre-prandial, inhalation.
Other Names:
Treat-to-target dose titration scheme, post-prandial, inhalation.
Other Names:
|
|
EXPERIMENTAL: A
|
Treat-to-target dose titration scheme, pre-prandial, inhalation.
Other Names:
Treat-to-target dose titration scheme, post-prandial, inhalation.
Other Names:
|
|
ACTIVE_COMPARATOR: C
|
Tablets, 2000 mg/day.
Tablets, 4 mg/day.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HbA1c change from baseline
Time Frame: After 18 weeks of treatment
|
After 18 weeks of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse events
Time Frame: For the duration of the trial
|
For the duration of the trial
|
|
Body weight
Time Frame: after 18 weeks of treatment
|
after 18 weeks of treatment
|
|
Lung function
Time Frame: after 18 weeks of treatment
|
after 18 weeks of treatment
|
|
Blood glucose
Time Frame: after 18 weeks of treatment
|
after 18 weeks of treatment
|
|
Hypoglycaemia
Time Frame: after 18 weeks of treatment
|
after 18 weeks of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN1998-1787
- 2006-004623-12 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.